Recent insider activity at Recursion Pharmaceuticals consisted of 3 Tax Payment transactions by 3 insiders, totaling $437,905.65 across 111,490 shares on November 16, 2026. Average transaction value ...
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...
RXRX is trading in the middle of its 52-week range and below its 200-day simple moving average. Price change The price of RXRX shares has decreased $0.10 since the market last closed. This is a 3.72% ...
Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...
Our subscribers support more than 180 years of science journalism. You get the facts, and you help us ensure that science is shared with rigor and independence.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results